Maternal and Fetal Outcome After Long-Term Pamidronate Treatment Before Conception: A Report of Two Cases
- 1 October 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (10) , 1742-1745
Abstract
The pregnancies of two women with osteogenesis imperfecta who received intravenous pamidronate before conception are reported. The mothers suffered no ill effects. One baby had transient asymptomatic hypocalcemia and one had bilateral talipes equinovarus. This report documents the pregnancy outcomes of two women with osteogenesis imperfecta (OI), types I and IV, who received intravenous pamidronate as part of an observational trial before conception. Pamidronate was not administered after conception. Other than hyperemesis in one woman, the pregnancies and deliveries were uneventful. Both babies inherited OI from their mothers. The baby with OI type IV also had bilateral talipes equinovarus. Biochemical evaluation of the mothers and babies at 24 h and/or 2 weeks postpartum was normal, apart from one baby with asymptomatic hypocalcemia at 24 h of age that had resolved when next measured on day 11 of life. No biochemistry was available on the second child until 13 days of age. Neither baby had skeletal modeling abnormalities consistent with in utero pamidronate exposure. The lumbar spine (L1-L4) areal BMD and anterior to posterior height ratios of lumbar vertebral bodies of both women remained constant during pregnancy. Both the mothers and babies remain well and free of fracture 14 and 16 months postpartum.Keywords
This publication has 11 references indexed in Scilit:
- Osteogenesis imperfectaThe Lancet, 2004
- Do Bisphosphonates Make Children's Bones Better or Brittle?New England Journal of Medicine, 2003
- Musculo-skeletal problems associated with pregnancy in women with osteogenesis imperfectaJournal of Obstetrics and Gynaecology, 2002
- A Detailed Assessment of Alterations in Bone Turnover, Calcium Homeostasis, and Bone Density in Normal PregnancyJournal of Bone and Mineral Research, 2000
- Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in ratsTeratology, 1999
- Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 1997
- Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronateClinical Oncology, 1996
- Effects of the Bisphosphonate, Alendronate, on Parturition in the RatToxicology and Applied Pharmacology, 1993
- Lumbar bone mineral content measured by dual energy X‐ray absorptiometry in newborns and infantsActa Paediatrica, 1992
- Antenatal administration of aminopropylidene diphosphonate.Annals of the Rheumatic Diseases, 1990